Related references
Note: Only part of the references are listed.An overview of binimetinib for the treatment of melanoma
Pol Specenier
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
Mu Yuxin et al.
FRONTIERS IN ONCOLOGY (2020)
Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
Ming-zhi Xie et al.
BMC GASTROENTEROLOGY (2019)
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing
Lise Boussemart et al.
ONCOLOGIST (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RET-fusions: a novel paradigm in colorectal cancer
C. Santos et al.
ANNALS OF ONCOLOGY (2018)
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma
A. Marchand et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing
Adam Waalkes et al.
CLINICAL CHEMISTRY (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis
Navid Sobhani et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
DNA mismatch repair in cancer
Marina Baretti et al.
PHARMACOLOGY & THERAPEUTICS (2018)
MEK inhibitors for the treatment of NRAS mutant melanoma
Saro Sarkisian et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F. Rimawi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Binimetinib for the treatment of NRAS-mutant melanoma
Paola Queirolo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Ines Marmol et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Rick Kamps et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2017)
Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer
Elizabeth P. Garcia et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers
Sofia Levva et al.
CANCER GENOMICS & PROTEOMICS (2017)
Pathogenesis and heterogeneity of ovarian cancer
Paul T. Kroeger et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
Zsofia K. Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Microsatellite instability in melanoma: a comprehensive review
Ondrej Kubecek et al.
MELANOMA RESEARCH (2016)
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
Andrew Rankin et al.
ONCOLOGIST (2016)
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Siraj M. Ali et al.
ONCOLOGIST (2016)
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Giuseppe V. Masucci et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2015)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas
Kui Wu et al.
NATURE COMMUNICATIONS (2015)
Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study
H. Eriksson et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The Influence of TP53 Mutations on the Prognosis of Patients With Early Stage Non-Small Cell Lung Cancer May Depend on the Intratumor Heterogeneity of the Mutations
Shin Yup Lee et al.
MOLECULAR CARCINOGENESIS (2015)
VHL, the story of a tumour suppressor gene
Lucy Gossage et al.
NATURE REVIEWS CANCER (2015)
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Harry H. Yoon et al.
CLINICAL CANCER RESEARCH (2014)
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit et al.
CLINICAL CANCER RESEARCH (2014)
Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study
Andrea Maurichi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases
Charles M. Balch et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Dariush Etemadmoghadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Chiara Scoccianti et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
Somaia Elbauomy Elsheikh et al.
BREAST CANCER RESEARCH (2007)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
M Olivier et al.
CLINICAL CANCER RESEARCH (2006)
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
GM Kraehn et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
